重症筋無力症治療の世界市場レポート 2024年

重症筋無力症治療の市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には7.5%の年間複合成長率（CAGR）で20億5,000万米ドルに成長すると予想されます。今後の期間に予想される成長は、生物製剤やモノクローナル抗体の使用増加、遺伝医療や精密医療の進歩、新たな免疫調節剤の台頭、神経保護戦略やバイオシミラー医薬品の導入などの要因に関連しています。予測期間中に予想される主要動向には、デジタル治療法の導入、共同調査の取り組み、患者中心のアプローチ、現実世界の証拠の活用、長期的な安全性モニタリングの実施などが含まれます。

予想される重症筋無力症の有病率の増加は、将来の重症筋無力症治療市場の成長を促進すると予想されます。重症筋無力症は、骨格筋の疲労と衰弱を引き起こす自己免疫性の神経筋課題を特徴とし、効果的な管理には包括的な医療サービスが必要です。重症筋無力症の症例の急増は、重症筋無力症治療市場内の売上高の増加に貢献しています。たとえば、希少疾患患者を支援する米国拠点の非営利団体である国立希少疾患機構のデータによると、2022年1月の米国における推定有病率は10万人当たり14～40人であることが明らかになった。イランに本拠を置くケルマーンシャー医科大学とマレーシア・プトラ大学は2021年12月に、重症筋無力症の世界有病率を10万人当たり12.4人と推定しました。したがって、重症筋無力症の有病率の増加は、重症筋無力症治療市場の成長の重要な原動力となっています。

重症筋無力症治療市場の成長は、医療支出の増加によって推進されています。医療支出は、特定の地域、国、または組織内の医療部門に割り当てられる財源の総額を指し、重症筋無力症などの自己免疫性神経筋障害に対処するために重要です。この財政的取り組みにより、最適な患者ケア、効果的な症状管理、そして全体的な生活の質の向上が保証されます。たとえば、2023年 3月の米国医師協会によると、米国の医療支出は2021年に2.7%増加し、4兆3,000億米ドルに達しました。これは一人当たり1万2,914ドルに相当します。したがって、医療支出の増加傾向は、重症筋無力症治療市場の成長を促進する重要な要因となります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の重症筋無力症治療市場の促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の重症筋無力症治療の市場規模実績と成長、2018～2023年
• 世界の重症筋無力症治療市場規模と成長予測、2023～2028年、2033年

第6章 市場セグメンテーション

• 世界の重症筋無力症治療市場、治療別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 薬
• 手術
• その他
• 世界の重症筋無力症治療市場、薬剤タイプ別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• コリンエステラーゼ阻害剤
• コルチコステロイド
• 免疫抑制剤
• その他
• 世界の重症筋無力症治療市場、最終用途別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
• 病院
• クリニック
• その他

第7章 地域と国の分析

• 世界の重症筋無力症治療市場、地域別、実績と予測、2018～2023年、2023～2028年、2033年
• 世界の重症筋無力症治療市場、国別、実績と予測、2018～2023年、2023～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 重症筋無力症治療市場の競合情勢
• 重症筋無力症治療市場の企業プロファイル
  • Pfizer Inc.
  • F. Hoffmann-La Roche Ltd.
  • AbbVie Inc.
  • Novartis AG
  • AstraZeneca plc

第31章 その他の大手と革新的な企業

• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Baxter International Inc.
• Biogen Idec
• Astellas Pharma Inc.
• CSL Limited
• Chugai Pharmaceutical Co. Ltd.
• Grifols SA
• UCB Inc.
• Mitsubishi Tanabe Pharma Corp.
• Genentech Inc.
• Horizon Therapeutics plc
• Amneal Pharmaceuticals Inc.
• Zydus Lifesciences Limited
• Kedrion SpA

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の展望と潜在性分析

第36章 付録

Myasthenia gravis treatment encompasses the provision of healthcare services by healthcare providers to address and manage myasthenia gravis, an autoimmune neuromuscular disease characterized by fatigue and weakness in the skeletal muscles.

The primary modalities for treating myasthenia gravis include medication, surgery, and other interventions. Medication involves the use of drugs to alleviate the symptoms associated with myasthenia gravis. One commonly prescribed medication is pyridostigmine, which facilitates the transmission of electrical signals between nerves and muscles. The treatment approach for myasthenia gravis incorporates various types of medications, such as cholinesterase inhibitors, corticosteroids, immunosuppressants, and others. These medications are administered in healthcare settings, including hospitals, clinics, and other healthcare facilities, to effectively manage the condition and improve the quality of life for patients.

The myasthenia gravis treatment market research report is one of a series of new reports from The Business Research Company that provides myasthenia gravis treatment market statistics, including myasthenia gravis treatment industry global market size, regional shares, competitors with a myasthenia gravis treatment market share, detailed myasthenia gravis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the myasthenia gravis treatment industry. This myasthenia gravis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The myasthenia gravis treatment market size has grown strongly in recent years. It will grow from $1.42 billion in 2023 to $1.54 billion in 2024 at a compound annual growth rate (CAGR) of 8.1%. The expansion observed in the preceding timeframe can be credited to the adoption of cholinesterase inhibitors, advancements in thymectomy procedures, the implementation of immunosuppressive therapies, the introduction of plasma exchange, and heightened patient advocacy efforts.

The myasthenia gravis treatment market size is expected to see strong growth in the next few years. It will grow to $2.05 billion in 2028 at a compound annual growth rate (CAGR) of 7.5%. The anticipated growth in the upcoming period is linked to factors such as the increased use of biologics and monoclonal antibodies, advancements in genetic and precision medicine, the rise of emerging immune modulators, and the implementation of neuroprotective strategies and biosimilar medications. Key trends expected during the forecast period encompass the adoption of digital therapeutics, collaborative research initiatives, patient-centric approaches, the utilization of real-world evidence, and the implementation of long-term safety monitoring.

The anticipated increase in the prevalence of myasthenia gravis is expected to drive the growth of the myasthenia gravis treatment market in the future. Myasthenia gravis, characterized by autoimmune neuromuscular challenges leading to fatigue and weakness in skeletal muscles, necessitates comprehensive healthcare services for effective management. The surge in myasthenia gravis cases is contributing to heightened sales within the myasthenia gravis treatment market. For instance, data from the National Organization for Rare Disorders, a US-based non-profit supporting individuals with rare diseases, revealed an estimated prevalence of 14-40 cases per 100,000 individuals in the United States in January 2022. Similarly, a study conducted by the Iran-based Kermanshah University of Medical Sciences and University Putra Malaysia in December 2021 estimated a global prevalence of 12.4 people per 100,000 for myasthenia gravis. Consequently, the increasing prevalence of myasthenia gravis is a significant driver of growth in the myasthenia gravis treatment market.

The growth of the myasthenia gravis treatment market is being propelled by the rise in healthcare spending. Healthcare spending, denoting the total financial resources allocated to the healthcare sector within a specific region, country, or organization, is crucial for addressing autoimmune neuromuscular disorders such as myasthenia gravis. This financial commitment ensures optimal patient care, effective symptom management, and an overall enhanced quality of life. For instance, according to the American Medical Association in March 2023, health spending in the United States witnessed a 2.7% increase in 2021, reaching $4.3 trillion, equivalent to $12,914 per capita. Consequently, the upward trajectory in healthcare spending is a key factor driving the growth of the myasthenia gravis treatment market.

The myasthenia gravis treatment market is witnessing a prominent trend towards product innovations, with major companies actively engaged in the development of novel solutions to enhance their market standing. A case in point is Argenx SE, a Netherlands-based biopharmaceutical company, which secured approval from the U.S. Food and Drug Administration (FDA) in December 2021 for its groundbreaking drug, VYVGARTo (efgartigimod alfa-fcab). Specifically designed for the treatment of anti-acetylcholine receptor (AChR) antibody-positive adult patients with generalized myasthenia gravis, VYVGART stands out as the first and only FDA-approved neonatal Fc receptor (FcRn) blocker in the realm of generalized myasthenia gravis treatment. Argenx SE has further solidified its market position by entering into agreements in principle with various regional and national commercial payers, establishing value-based agreements to ensure patient access and cost predictability.

Major players in the myasthenia gravis treatment market are strategically embracing partnerships to usher in a patient-centric approach and redefine the delivery of care to rare disease populations. Strategic partnerships, characterized by the mutual leveraging of strengths and resources, have become a key avenue for collaboration. An illustrative example is the partnership between Huma Therapeutics, a UK-based digital health company, and UCB S.A., a Belgium-based biopharmaceutical company, announced in April 2023. This collaboration aims to introduce a digital health solution to enhance the management of the rare disease Myasthenia gravis (MG).

In December 2021, Merck, a Germany-based pharmaceutical company, executed the acquisition of Chord Therapeutics, a Switzerland-based pharmaceutical company, for an undisclosed amount. This strategic move empowered Merck by incorporating cladribine into its pipeline and acquiring rights to develop cladribine for generalized myasthenia gravis (gMG). Cladribine, known for its therapeutic impact on B and T cells, key contributors to autoimmune diseases such as generalized myasthenia gravis, expanded Merck's neuroinflammatory disease portfolio. This acquisition complemented Merck's existing neurology portfolio in multiple sclerosis (MS), reinforcing its presence in the neuroinflammatory disease domain.

Major companies operating in the myasthenia gravis treatment market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Baxter International Inc., Biogen Idec, Astellas Pharma Inc., CSL Limited, Chugai Pharmaceutical Co. Ltd., Grifols S.A, UCB Inc., Mitsubishi Tanabe Pharma Corp., Genentech Inc., Horizon Therapeutics PLC, Amneal Pharmaceuticals Inc., Zydus Lifesciences Limited, Kedrion SpA, CuraVac Inc., AryoGen Pharmed, RemeGen Co. Ltd., Kashiv BioSciences LLC, Avadel Pharmaceuticals PLC, Immunovant Inc., Cabaletta Bio Inc., Argenx SE, NMD Pharma A/S, Cartesian Therapeutics Inc., DAS Therapeutics Inc., Harbour BioMed Holdings Ltd., Zenyaku Kogyo Co. Ltd., AnTolRx Inc., CytoDyn Inc., Ahead Therapeutics

North America was the largest region in the myasthenia gravis treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the myasthenia gravis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the myasthenia gravis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The myasthenia gravis treatment market consists of sales of pyridostigmine, prednisone, azathioprine, and cyclosporine. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Myasthenia Gravis Treatment Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on myasthenia gravis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for myasthenia gravis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The myasthenia gravis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Treatment: Medication; Surgery; Other Treatments
• 2) By Medication Type: Cholinesterase Inhibitors; Corticosteroids; Immunosuppressants; Other Medication Types
• 3) By End-Use: Hospitals; Clinics; Other End-Uses
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; AbbVie Inc.; Novartis AG; AstraZeneca plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Myasthenia Gravis Treatment Market Characteristics

3. Myasthenia Gravis Treatment Market Trends And Strategies

4. Myasthenia Gravis Treatment Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Myasthenia Gravis Treatment Market Size and Growth

• 5.1. Global Myasthenia Gravis Treatment Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Myasthenia Gravis Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Myasthenia Gravis Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Myasthenia Gravis Treatment Market Segmentation

• 6.1. Global Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Medication
• Surgery
• Other Treatments
• 6.2. Global Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Cholinesterase Inhibitors
• Corticosteroids
• Immunosuppressants
• Other Medication Types
• 6.3. Global Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospitals
• Clinics
• Other End-Uses

7. Myasthenia Gravis Treatment Market Regional And Country Analysis

• 7.1. Global Myasthenia Gravis Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Myasthenia Gravis Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Myasthenia Gravis Treatment Market

• 8.1. Asia-Pacific Myasthenia Gravis Treatment Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Myasthenia Gravis Treatment Market

• 9.1. China Myasthenia Gravis Treatment Market Overview
• 9.2. China Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Myasthenia Gravis Treatment Market

• 10.1. India Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Myasthenia Gravis Treatment Market

• 11.1. Japan Myasthenia Gravis Treatment Market Overview
• 11.2. Japan Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Myasthenia Gravis Treatment Market

• 12.1. Australia Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Myasthenia Gravis Treatment Market

• 13.1. Indonesia Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Myasthenia Gravis Treatment Market

• 14.1. South Korea Myasthenia Gravis Treatment Market Overview
• 14.2. South Korea Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Myasthenia Gravis Treatment Market

• 15.1. Western Europe Myasthenia Gravis Treatment Market Overview
• 15.2. Western Europe Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Myasthenia Gravis Treatment Market

• 16.1. UK Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Myasthenia Gravis Treatment Market

• 17.1. Germany Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Myasthenia Gravis Treatment Market

• 18.1. France Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Myasthenia Gravis Treatment Market

• 19.1. Italy Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Myasthenia Gravis Treatment Market

• 20.1. Spain Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.15. Spain Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Myasthenia Gravis Treatment Market

• 21.1. Eastern Europe Myasthenia Gravis Treatment Market Overview
• 21.2. Eastern Europe Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Myasthenia Gravis Treatment Market

• 22.1. Russia Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Myasthenia Gravis Treatment Market

• 23.1. North America Myasthenia Gravis Treatment Market Overview
• 23.2. North America Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Myasthenia Gravis Treatment Market

• 24.1. USA Myasthenia Gravis Treatment Market Overview
• 24.2. USA Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Myasthenia Gravis Treatment Market

• 25.1. Canada Myasthenia Gravis Treatment Market Overview
• 25.2. Canada Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Myasthenia Gravis Treatment Market

• 26.1. South America Myasthenia Gravis Treatment Market Overview
• 26.2. South America Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Myasthenia Gravis Treatment Market

• 27.1. Brazil Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Myasthenia Gravis Treatment Market

• 28.1. Middle East Myasthenia Gravis Treatment Market Overview
• 28.2. Middle East Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Myasthenia Gravis Treatment Market

• 29.1. Africa Myasthenia Gravis Treatment Market Overview
• 29.2. Africa Myasthenia Gravis Treatment Market, Segmentation By Treatment, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Myasthenia Gravis Treatment Market, Segmentation By Medication Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Myasthenia Gravis Treatment Market, Segmentation By End-Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Myasthenia Gravis Treatment Market Competitive Landscape And Company Profiles

• 30.1. Myasthenia Gravis Treatment Market Competitive Landscape
• 30.2. Myasthenia Gravis Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. F. Hoffmann-La Roche Ltd.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. AbbVie Inc.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Novartis AG
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. AstraZeneca plc
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Myasthenia Gravis Treatment Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline plc
• 31.2. Takeda Pharmaceutical Company Limited
• 31.3. Baxter International Inc.
• 31.4. Biogen Idec
• 31.5. Astellas Pharma Inc.
• 31.6. CSL Limited
• 31.7. Chugai Pharmaceutical Co. Ltd.
• 31.8. Grifols S.A
• 31.9. UCB Inc.
• 31.10. Mitsubishi Tanabe Pharma Corp.
• 31.11. Genentech Inc.
• 31.12. Horizon Therapeutics plc
• 31.13. Amneal Pharmaceuticals Inc.
• 31.14. Zydus Lifesciences Limited
• 31.15. Kedrion SpA

32. Global Myasthenia Gravis Treatment Market Competitive Benchmarking

33. Global Myasthenia Gravis Treatment Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Myasthenia Gravis Treatment Market

35. Myasthenia Gravis Treatment Market Future Outlook and Potential Analysis

• 35.1 Myasthenia Gravis Treatment Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Myasthenia Gravis Treatment Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Myasthenia Gravis Treatment Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer